Litigation Details for Intercept Pharmaceuticals, Inc. v. Optimus Pharma Pvt. Ltd. (D. Del. 2020)

✉ Email this page to a colleague

Intercept Pharmaceuticals, Inc. v. Optimus Pharma Pvt. Ltd. (D. Del. 2020)

Docket	⤷ Start Trial	Date Filed	2020-09-11
Court	District Court, D. Delaware	Date Terminated	2023-01-17
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	None	Referred To
Patents	10,047,117; 10,052,337; 10,174,073; 10,751,349; 10,758,549; 7,138,390; 9,238,673; RE48,286
Link to Docket	External link to docket

Small Molecule Drugs cited in Intercept Pharmaceuticals, Inc. v. Optimus Pharma Pvt. Ltd.

The small molecule drug covered by the patents cited in this case is ⤷ Start Trial .

Details for Intercept Pharmaceuticals, Inc. v. Optimus Pharma Pvt. Ltd. (D. Del. 2020)

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Date Filed	Document No.	Description	Snippet	Link To Document
2020-09-11				External link to document
2020-09-11	13	SO ORDERED	Stipulation to Substitute U.S. Patent No. RE48,286 for U.S. Patent No. 7,138,390. Signed by Judge Maryellen…2020 17 January 2023 1:20-cv-01215 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2020-09-11	17	Complaint - Amended	the ’673 patent”); 10,047,117 (filed Nov. 20, 1 The RE286 Patent is a reissue of U.S. Patent No. 7,138,390…or Non-Infringement for U.S. Patent Nos. 7,138,390; 9,238,673; 10,047,117; 10,052,337; and 10,174,073 …073 patent”); and 10,758,549 (filed Feb. 11, 2020) (“the ’549 patent”) (collectively the “patents-in-… 1. This action for patent infringement, brought pursuant to the patent laws of the United States… expiration of U.S. Patent Nos. RE48,286 (filed June 21, 2019) (“the RE286 patent”);1 9,238,673 (filed	External link to document
2020-09-11	18	Patent/Trademark Report to Commissioner of Patents	Commissioner of Patents and Trademarks for Patent/Trademark Number(s)RE48,286; 9,238,673; 10,047,117; 10,052,…11 September 2020 1:20-cv-01215 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Intercept Pharmaceuticals v. Optimus Pharma (1:20-cv-01215): Litigation Summary, Patent Issues, and Key Entry Risks

Last updated: July 5, 2026

Intercept Pharmaceuticals, Inc. v. Optimus Pharma Pvt. Ltd., No. 1:20-cv-01215 (D. Del.) is a Hatch-Waxman patent infringement dispute tied to Optimus’s FDA pathway and planned generic entry for Intercept’s marketed product (U.S. use of Intercept’s portfolio appears implicated). The case posture and core leverage are standard for Orange Book-driven litigation: Intercept asserts that Optimus’s proposed product infringes one or more Orange Book-listed patents (and that Optimus’s certifications are not valid), while Optimus disputes infringement and/or invalidity and presses for noninfringing design-around and/or patent invalidity. The immediate business question is whether Intercept’s asserted patents are likely to survive early merits stages and, if so, whether Optimus can launch without running into an injunction or stay tied to the outcome of the case.

No reliable, complete litigation docket facts (asserted patents, filing date, infringement claims, paragraph IV certifications, settlement terms, Markman rulings, dispositive motions, or final judgment) are provided in the prompt. Under the operating constraint, this response cannot produce a complete and accurate litigation summary and analysis without those docket-specific details.

What happened in Intercept Pharmaceuticals, Inc. v. Optimus Pharma Pvt. Ltd. 1:20-cv-01215?

Answer: The case is a Delaware Hatch-Waxman-style patent infringement action filed by Intercept against Optimus Pharma Pvt. Ltd., identified by docket number 1:20-cv-01215. The dispute centers on whether Optimus’s FDA-submitted generic plan infringes Intercept’s Orange Book-listed patents for the relevant branded product.